S&P 5007,509.20▲0.9% Nasdaq25,837.21▲1.3% Dow52,224.64▲0.7% Russell 2K2,987.40▲1.5% 10-Yr4.63%+3bp VIX17.55+0.50 WTI$87.52▲3.1% Gold$4,117.00▲1.1% EUR/USD1.141▼0.0% BTC$65,497▼0.9% Nikkei66,116▼0.2%
At close · Wed, Jul 22, 2026
Daily Market Updates.

Earnings

Home›Earnings›Previews›Eli Lilly targets 2027 approval filing for retatrutide…

Eli Lilly targets 2027 approval filing for retatrutide obesity drug

The company says retatrutide now has positive results from five late-stage trials as it advances two more studies.

Reported · Written up by our desk · Previews

Eli Lilly said it plans to file for regulatory approval of retatrutide, its next-generation obesity drug, in 2027, according to CNBC Markets and CNBC World.

The outlets reported that Lilly is positioning retatrutide as a potential next pillar of its obesity portfolio.

Lilly said retatrutide has generated positive results across five late-stage trials, and it has also cleared two additional trials as it continues to advance the program.

The company’s 2027 filing plan comes as it moves the drug through late-stage development after the latest trial results.

← Newer storyBitwise expects Hyperliquid and Robinhood ventures to lift Bitcoin

More like this

EarningsComcast earnings spotlight NBCUniversal strength before planned split
EarningsTesla heads into Q2 earnings after 480,126 deliveries in the quarter
EarningsInfosys set to report Q1 FY27 results, with guidance in focus
EarningsAlphabet and Tesla slide as AI spending swells in earnings reports
EarningsInvestors weigh Alphabet results as AI spending rises

Sources

CNBC MarketsEli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
CNBC WorldEli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.